Your browser doesn't support javascript.
loading
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
Andeweg, Stijn P; de Gier, Brechje; Eggink, Dirk; van den Ende, Caroline; van Maarseveen, Noortje; Ali, Lubna; Vlaemynck, Boris; Schepers, Raf; Hahné, Susan J M; Reusken, Chantal B E M; de Melker, Hester E; van den Hof, Susan; Knol, Mirjam J.
Afiliação
  • Andeweg SP; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Gier B; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Eggink D; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van den Ende C; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van Maarseveen N; Saltro Diagnostic Center for Primary Care, Utrecht, The Netherlands.
  • Ali L; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Vlaemynck B; Saltro Diagnostic Center for Primary Care, Utrecht, The Netherlands.
  • Schepers R; SYNLAB, Heppignies, Belgium.
  • Hahné SJM; SYNLAB, Heppignies, Belgium.
  • Reusken CBEM; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Melker HE; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van den Hof S; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Knol MJ; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Nat Commun ; 13(1): 4738, 2022 08 12.
Article em En | MEDLINE | ID: mdl-35961956
ABSTRACT
Given the emergence of the SARS-CoV-2 Omicron BA.1 and BA.2 variants and the roll-out of booster COVID-19 vaccination, evidence is needed on protection conferred by primary vaccination, booster vaccination and previous SARS-CoV-2 infection by variant. We employed a test-negative design on S-gene target failure data from community PCR testing in the Netherlands from 22 November 2021 to 31 March 2022 (n = 671,763). Previous infection, primary vaccination or both protected well against Delta infection. Protection against Omicron BA.1 infection was much lower compared to Delta. Protection was similar against Omicron BA.1 compared to BA.2 infection after previous infection, primary and booster vaccination. Higher protection was observed against all variants in individuals with both vaccination and previous infection compared with either one. Protection against all variants decreased over time since last vaccination or infection. We found that primary vaccination with current COVID-19 vaccines and previous SARS-CoV-2 infections offered low protection against Omicron BA.1 and BA.2 infection. Booster vaccination considerably increased protection against Omicron infection, but decreased rapidly after vaccination.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda